Acquisition
Nov 2023Viome acquired Naring Health and its subsidiaries DiscernDx and Foodome, expanding its personalized nutrition and diagnostics capabilities.
SourceCompany research
Public company, workplace, funding, and market signals
Overview
Viome is a Bellevue-based health technology company that uses metatranscriptomic RNA analysis and AI to turn human and microbial gene expression into personalized food, supplement, oral-health, and early-detection recommendations.
Primary product
At-home microbiome and full-body intelligence tests with personalized nutrition and precision supplement recommendations
Founded
2016
Headquarters
Bellevue, Washington, United States
Team size
50-60
Industry
Wellness and Fitness Services
Sub-industry
Microbiome health tests, personalized nutrition, and RNA-based diagnostics
Offices
Bellevue, Washington, United States
Bothell, Washington, United States
New York, New York, United States
Business model
Direct-to-consumer at-home diagnostic tests
Funding
Stage
Series D
Total raised
$301M
Latest round
Series D · Sep 2024
Latest amount
$25M
People & investors
Leadership
Founder & CEO
Founding CTO & Head of Discovery AI
Founding CSO & Head of Clinical Research
Work & culture
Mission-driven, science-forward, and consumer-education oriented; public materials emphasize food as medicine, precision health, community engagement, STEM outreach, and using AI and biology to prevent chronic disease.
Compensation
Public job postings show role-level pay transparency for some positions; one public posting listed Senior Product Manager, Consumer at $150k-$180k/year. Broader compensation bands are not publicly disclosed.
Benefits
Employer-paid medical, dental, and vision coverage
100% coverage for basic life, AD&D, and long-term disability
401(k) plan
Flexible time off
Paid sick days
Product & market
Pricing
One-time at-home test purchases plus recurring subscription bundles for personalized supplements, probiotics, prebiotics, toothpaste, and oral lozenges; some clinician/retail diagnostic products are sold separately.
Differentiators
- —Uses RNA/metatranscriptomic analysis rather than DNA-only testing
- —Measures both human and microbial gene expression
- —AI-driven recommendations update with dynamic biology over time
- —Combines diagnostics with personalized food and supplement guidance
- —Offers oral, gut, and full-body health products in one platform
- —Has CLIA-lab backed testing and FDA Breakthrough Device-designated cancer detection work
Technology
Java
Scala
Scale & contact
Estimated revenue
About $138M annually (reported range roughly $100M-$150M)
Estimated monthly visits
206.6K
Traffic estimate as of Jun 2026
Signals & risks
Latest news
Scripps Research · Jul 2025
Viome and Scripps Research announced a 1,000-patient study to validate an at-home RNA test for precancerous colon polyps, extending Viome’s diagnostics work beyond oral and throat cancer.
PR Newswire · Jul 2025
Viome announced a collaboration with Microsoft Azure to scale its RNA and AI platform for preventive and personalized healthcare.
PR Newswire · Apr 2025
Viome launched its most comprehensive consumer test, emphasizing dynamic biology, AI-driven recommendations, and broader health scoring.
GeekWire · Sep 2024
Viome raised a $25 million Series D and hired Kal Raman as COO to help expand its diagnostics division.
Open Positions
3 jobs at Viome
Senior Platform Operations Engineer, Infrastucture
On-siteBellevue, WA3d ago
On-site
Full-time